Recombinant human hyaluronidase + immune globulin intravenous
160602
Phase 2 mab completed
Quick answer
Recombinant human hyaluronidase + immune globulin intravenous for Primary Immunodeficiency Diseases (PID) is a Phase 2 program (mab) at Takeda with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Takeda
- Indication
- Primary Immunodeficiency Diseases (PID)
- Phase
- Phase 2
- Modality
- mab
- Status
- completed